Related Experiment Video
Updated: May 22, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Dabigatran in patients with atrial fibrillation: perioperative and periinterventional management
A Weltermann1, M Brodmann, H Domanovits
1Department of Medicine I, Elisabethinen Hospital Linz, Fadinger Straße 1, 4020, Linz, Austria. ansgar.weltermann@elisabethinen.or.at
Insights
Managing patients on dabigatran requires balancing bleeding and thromboembolism risks during surgery. Expert recommendations focus on patient history, dosing intervals, and hemostasis control due to a lack of routine lab monitoring.
Area of Science:
- Cardiology
- Pharmacology
- Surgical Management
Background:
- Balancing thromboembolism and bleeding risks is critical in invasive surgery.
- Atrial fibrillation patients often require long-term anticoagulation.
- Dabigatran is a direct thrombin inhibitor used for anticoagulation.
Purpose of the Study:
- To provide expert recommendations for perioperative management of atrial fibrillation patients on dabigatran.
- To address the clinical challenges in managing dabigatran therapy during invasive procedures.
Main Methods:
- Development of expert recommendations based on clinical routine and expert consensus.
- Focus on general management strategies in the absence of specific laboratory monitoring.
Main Results:
- Standardized patient history documentation is crucial.
- Adequate time interval between the last dabigatran dose and the procedure is essential.
- Meticulous control of local hemostasis is paramount.
Conclusions:
- Perioperative management of dabigatran requires careful consideration of individual patient factors.
- General measures are key due to the lack of routine laboratory tests for dabigatran levels or bleeding risk.
- These recommendations aim to optimize patient safety during invasive procedures.
Abstract:
In any type of invasive surgery, the patient's individual risk of thromboembolism has to be weighed against the risk of bleeding. Based on various everyday situations in clinical routine, the purpose of the present expert recommendations is to provide appropriate perioperative and periinterventional management for patients with atrial fibrillation undergoing long-term treatment with the thrombin inhibitor dabigatran. As we currently have no routine laboratory test to measure therapeutic levels of the substance or the risk of bleeding, general measures such as a standardized documentation of the patient's history, a sufficient time interval between the last preoperative dose and the procedure, and careful control of local hemostasis should be given special attention.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Aneurysm IV: Nursing Management
Venous Thrombosis IV: Nursing Management
Pulmonary Embolism III: Nursing Management
